[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laure Pittet, MD-PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100551671","registry-of-vaccine-responses-in-immune-compromised-patients-100551671",false,"NCT06463119","Registry of Vaccine Responses in Immune Compromised Patients","REVAPI","Inclusion Criteria:\n\n1. Immune compromised patient or patient who will soon be immunocompromised\n2. Informed consent as documented by signature\n\nExclusion Criteria:\n\n1. Individual\u002Fparental inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, known\u002Fsuspected non-compliance, substance abuse, etc.\n2. Plan to move out of the country or have prolong absence in the next 2 months","ALL",{"count":18,"type":19},300,"ESTIMATED","5 Years","OBSERVATIONAL","The aim of this project is to monitor, guide and document vaccination, vaccine responses, persistence of protection, vaccine efficacy and safety in immune compromised patients at various moment of their disease: right after the diagnosis, before the introduction of the immunosuppressive treatment, once the individual is under immunosuppressive treatment, or once immunosuppression is over.",[24],"Immunosuppression",[26],"Vaccine","RECRUITING","2024-11-06",{"date":30,"type":31},"2024-11-07","ACTUAL",{"date":33,"type":31},"2024-09-24",{"date":35,"type":19},"2029-04",{"name":37,"class":38},"Laure Pittet, MD-PhD","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100497537","phase-4-non-specific-effects-of-a-modified-measles-vaccination-schedule-to-prevent-allergy-and-unrelated-infection-in-children-100497537","NCT05758532","Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children","Harnessing the Beneficial Non-specific Effects of Measles-mumps-rubella Vaccine in Children on Infection With Unrelated Pathogens and Allergic Diseases - a Single-centre Phase IV RCT With a Factorial Design","NEMAU","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. 6-month-old children\n3. In overall good health, without any clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) and no clinically significant abnormal finding on history and\u002For physical examination\n4. Fully immunised for age according to the Swiss vaccination schedule\n\n   1. with at least 2 doses of DTP-containing vaccine\n   2. the last dose of vaccine received at least 2 weeks prior to enrolment\n\nExclusion Criteria:\n\n1. Contra-indications to MMR, including\n\n   1. immunosuppression (i.e. proven, suspected, or planned)\n   2. allergy to a component of the vaccine\n   3. receipt of a live-attenuated vaccine in the four weeks prior to inclusion\n2. Vaccine refusal\n3. Indication for an early MMR vaccination, including\n\n   1. Measles outbreak\n   2. Planned immunosuppression (indication to an accelerated schedule to be completed before starting an immunosuppressive treatment)\n   3. Travel to a region with a high risk of measles outbreak\n4. Indication for vaccination with MMR-varicella (MMRV) instead of MMR, including\n\n   1. severe eczema\n   2. parental will\n5. Parental inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, known\u002Fsuspected non-compliance, substance abuse, etc.\n6. Plan to move out of the country or have prolong absence during the trial\n7. Other sibling included in the trial (in the case of multiple pregnancy, only one child can be randomised)\n8. Any temporary contra-indication to MMR, including child being sick (active significant illness, inclusion can be delayed a few days until the illness resolves)",true,"6 Months",{"count":51,"type":19},500,"INTERVENTIONAL",[54],"PHASE4","The goal of this clinical trial is to evaluate the off-target\u002Fnon-specific effects of the measles-mumps-rubella (MMR) vaccine in children.",[57,58,59,60],"Respiratory Tract Infections","Infections","Allergy","Eczema",[62],"Non-specific\u002Foff-target effect of vaccine","2024-05-27",{"date":65,"type":31},"2024-05-29",{"date":67,"type":31},"2023-03-17",{"date":69,"type":19},"2026-12",{"name":37,"class":38},""]